Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11081210 | 1.00 | TSHR (0.71) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL2532324 | 1.00 | TSHR (0.71) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL29098933 | 1.00 | TSHR (0.71) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL822812 | 1.00 | TSHR (0.71) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL9083720 | 1.00 | TSHR (0.71) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL5434893 | 1.00 | TSHR (0.71) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL4495197 | 0.97 | MEN1 (0.74) | TSHRMEN1KMT2ATHRBHTT | |
| 1,4-Butanediol SCHEMBL9011697 | 0.97 | MEN1 (0.74) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL13500010 | 0.97 | MEN1 (0.74) | TSHRMEN1KMT2ATHRBHTT | |
| 1,6-Hexanediol SCHEMBL9011792 | 0.97 | MEN1 (0.74) | TSHRMEN1KMT2ATHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461135-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-12034122-B2 | Electrolytic solution for lithium-ion secondary battery and lithium-ion secondary battery | MURATA MANUFACTURING CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| CN-112074983-B | Electrolyte for lithium ion secondary battery and lithium ion secondary battery | 株式会社村田制作所 | 2024-06-04 | — | — | CN | disclosed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| CN-117945866-A | Synthetic ether base oil and preparation method and application thereof | 亚培烯科技（杭州）有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| CN-115989005-A | Polyurethane composite sheet, method for producing a composite sheet and use thereof for producing medical implants | 帝斯曼知识产权资产管理有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| CN-110938339-B | Thermosetting release coating agent and laminated film | 日本化工涂料株式会社 | 2022-06-14 | — | — | CN | disclosed |
| US-5034395-A | Hypotensive agents, carboxylated dihydropyridines | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-23 | — | — | US | disclosed |
| US-4895910-A | COPOLYMER OF UNSATURATED POLYSILOXANE AND UNSATURATED ALICYCLIC-FUSED EPOXY COMPOUND AND AN ALUMINUM OR ZIRCONIUM CHELATE; ONE-PACKAGE; MATERIALS HANDLING | KANSAI PAINT COMPANY, LIMITED (JP) | 1990-01-23 | — | — | US | disclosed |
| US-4795814-A | CORONARY VASODILATORS, HYPOTENSIVE AGENTS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTTS, ENZYME INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-03 | — | — | US | disclosed |
| US-4772672-A | COATINGS | KANSAI PAINT COMPANY, LIMITED (JP) | 1988-09-20 | — | — | US | disclosed |
| US-4743383-A | ORGANOPHILIC CLAY, PREVENTION OF FLUID LOSS | PHILLIPS PETROLEUM COMPANY (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0173126-A1 | Process for preparing novel dihydropyridine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0145434-A2 | Novel dihydropyridine derivatives and process for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
| US-4407899-A | CORROSION RESISTANT PRIMERS | NIPPON KOKAN KABUSHIKI KAISHA (JP) | 1983-10-04 | — | — | US | disclosed |
| US-4230599-A | Process for inhibiting foaming utilizing maleic ester copolymer based defoamers, and defoamed compositions | THE DIVERSEY CORPORATION (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | TSHR 940/4885MEN1 4632/4885KMT2A 3278/4885 |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | TSHR 1289/4885MEN1 3825/4885KMT2A 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.